Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10561148 | 0.92 | ADRB2 (0.62) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10578945 | 0.90 | SPHK1 (0.62) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL9224604 | 0.89 | SPHK1 (0.51) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10580782 | 0.88 | SPHK1 (0.57) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL9513791 | 0.87 | ADRB2 (0.51) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10576426 | 0.86 | ADRB2 (0.51) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10577855 | 0.85 | ADRB2 (0.49) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10576581 | 0.84 | IGF1R (0.46) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL10578956 | 0.83 | SPHK1 (0.44) | SPHK1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL2022249 | 0.82 | KCNH2 (0.78) | ADRB2ADRB1ADRB3KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4806536-A | Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents | PFIZER, INC. (US) | 1989-02-21 | — | — | US | claimed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-0233051-B1 | ANTIARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1993-09-15 | — | — | EP | disclosed |
| US-4806536-A | Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents | PFIZER, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0233051-A2 | Antiarrhythmic Agents | Pfizer Limited (GB) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | SPHK1 472/4885ADRB2 1593/4885ADRB1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.